Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144 - 26/06/12

Doi : 10.1016/S1473-3099(12)70088-9

Merlin L Robb, MD ^a, Supachai Rerks-Ngarm, MD ^b, Sorachai Nitayaphan, MD ^c, Punnee Pitisuttithum, ProfMD ^e, Jaranit Kaewkungwal, PhD ^f,^g, Prayura Kunasol, MD ^b, Chirasak Khamboonruang, MD ^b, Prasert Thongcharoen, ProfMD ^b, Patricia Morgan, MS ^d,^h, Michael Benenson, MD ^d,^h, Robert M Paris, MD ⁱ, Joseph Chiu, MD ^j, Elizabeth Adams, MD ^j, Donald Francis, MD ^k, Sanjay Gurunathan, MD ^l, Jim Tartaglia, PhD ^l, Peter Gilbert, PhD ^m, Don Stablein, PhD ⁿ, Nelson L Michael, MD ^a, Jerome H Kim, DrMD ^a,^o,^⁎

^a US Military HIV Research Program, Division of Retrovirology, Walter Reed Army Institute of Research, Rockville, MD, USA

^b Department of Disease Control, Ministry of Public Health, Nonthaburi, Thailand

^c Thai Components, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand

^d US Army Components, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand

^e Vaccine Trials Centre, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand

^f Data Management Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand

^g Biophics, Bangkok, Thailand

^h Henry Jackson Foundation, Rockville, MD, USA

ⁱ Walter Reed Army Medical Center, Washington, DC, USA

^j National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA

^k Global Solutions for Infectious Diseases, South San Francisco, CA, USA

^l Sanofi Pasteur, Swiftwater, PA, USA

^m Fred Hutchinson Cancer Research Center, Seattle, WA, USA

ⁿ EMMES Corporation, Rockville, MD, USA

^o US Army Medical Materiel Development Activity, Fort Detrick, MD, USA

^* Correspondence to: Dr Jerome H Kim, 1600 E Gude Drive, Rockville, MD 20850, USA

Summary

Background

The Thai phase 3 HIV vaccine trial RV 144 showed modest efficacy of a vaccine against HIV acquisition. Baseline variables of age, sex, marital status, and risk did not modify vaccine efficacy. We did a post-hoc analysis of the trial’s data to investigate behavioural risk and efficacy every 6 months after vaccination.

Methods

RV 144 was a randomised, multicentre, double-blind, placebo-controlled efficacy trial testing the combination of the HIV vaccines ALVAC-HIV (vCP1521) and AIDSVAX B/E to prevent HIV infection or reduce setpoint viral load. Male and female volunteers aged 18–30 years were recruited from the community. In this post-hoc analysis of the modified intention-to-treat population (16395 participants), HIV risk behaviour was assessed with a self-administered questionnaire at the time of initial vaccination in the trial and every 6 months thereafter for 3 years. We classified participants’ behaviour as low, medium, or high risk. Both the acquisition endpoint and the early viral-load endpoint were examined for interactions with risk status over time and temporal effects after vaccination. Multiple proportional hazards regression models with treatment and time-varying risk covariates were analysed.

Findings

Risk of acquisition of HIV was low in each risk group, but 9187 (58·2%) participants reported higher-risk behaviour at least once during the study. Participants classified as high or increasing risk at least once during follow-up were compared with those who maintained low-risk or medium-risk behaviour as a time-varying covariate, and the interaction of risk status and acquisition efficacy was significant (p=0·01), with greater benefit in low-risk individuals. Vaccine efficacy seemed to peak early—cumulative vaccine efficacy was estimated to be 60·5% (95% CI 22–80) through the 12 months after initial vaccination—and declined quickly. Vaccination did not seem to affect viral load in either early or late infections.

Interpretation

Future HIV vaccine trials should recognise potential interactions between challenge intensity and risk heterogeneity in both population and treatment effects. The regimen tested in the RV 144 phase 3 trial might benefit from extended immunisation schedules.

Funding

US Army Medical Research and Materiel Command and Division of AIDS, National Institute of Allergy and Infectious Disease, National Institutes of Health.

Le texte complet de cet article est disponible en PDF.

Plan

Introduction

Methods

Study design and participants

Procedures

Statistical analysis

Role of the funding source

Results

Discussion

Export

Vol 12 - N° 7

P. 531-537 - juillet 2012 Retour au numéro

Article précédent

Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trial
Louise Kuhn, Ashraf Coovadia, Renate Strehlau, Leigh Martens, Chih-Chi Hu, Tammy Meyers, Gayle Sherman, Gillian Hunt, Deborah Persaud, Lynn Morris, Wei-Yann Tsai, Elaine J Abrams

| Article suivant

Burden of HIV among female sex workers in low-income and middle-income countries: a systematic review and meta-analysis
Stefan Baral, Chris Beyrer, Kathryn Muessig, Tonia Poteat, Andrea L Wirtz, Michele R Decker, Susan G Sherman, Deanna Kerrigan

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

connectez-vous ou créez un compte

Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144 - 26/06/12

Summary

Background

Methods

Findings

Interpretation

Funding

Plan

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL